CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 
Celgene Corp  (CELG)
Other Ticker:  
 
    Sector  Healthcare    Industry Major Pharmaceutical Preparations
 
 
Price: $124.0900 $-0.34 -0.273%
Day's High: $ 125.06 Week Perf: 0.71 %
Day's Low: $ 123.96 30 Day Perf: 0.47 %
Volume (M): 2,055 52 Wk High: $ 127.64
Volume (M$): $ 255,030 52 Wk Avg: $ 110.46
Open: 124.28 52 Wk Low: 94.42
  CELG Charts & Quotes
You need to upgrade your Flash Player

 Market Capitalization (Millions $) 99,582
 Shares Outstanding (Millions) 803
 Employees 6,012
 Revenues (TTM) (Millions $) 11,229
 Net Income (TTM) (Millions $) 1,999
 Cash Flow (TTM) (Millions $) 1,290
 Capital Exp. (TTM) (Millions $) 236
Celgene Corp
We are a multinational integrated biopharmaceutical company, incorporated in 1986 as a Delaware corporation. We are primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory-related diseases. Over the last several years, total revenues have steadily grown led by sales of THALOMID(R) (thalidomide), our lead product, which is currently marketed for the treatment of erythema nodosum leprosum, or ENL, but more widely used off-label for treating multiple myeloma and other cancers. The sales growth of THALOMID(R) has enabled us to make substantial investments in research and development, which has advanced our broad portfolio of drug candidates in our product pipeline, including a pipeline of IMiDs(R) compounds, which are a class of compounds proprietary to us and having certain immunomodulatory and other biologically important properties.


CELG is expected to report next financial results on April 24, 2017.
 

Celgene's Segments
 
REVLIMID
 Segment    62.85 % of total Revenue
THALOMID
 Segment    1.95 % of total Revenue
ABRAXANE
 Segment    9.94 % of total Revenue
VIDAZA
 Segment    6.38 % of total Revenue
Other
 Segment    0.12 % of total Revenue
Total product sales
 Segment    100 % of total Revenue
ISTODAX
 Segment    0.75 % of total Revenue
POMALYST, IMNOVID
 Segment    11.09 % of total Revenue
azacitidine injection
 Segment    0.92 % of total Revenue
 
  Company Estimates  
  Revenue Outlook
Celgene announced annual revenue outlook on Nov. 05, 2015

Earnings Outlook
Celgene Corp issued annual earnings guidance on Nov. 05, 2015

 
Geographic Revenue Dispersion
United States 59.47 %
All Other 11.8 %
Europe 28.73 %

Commercial Metals Co

Strong Eps Underlines Double Digits Sales Growth

For the second quarter earnings per share more than doubled by 188.89 % to $0.26 per share, followed by Sales increase of 12.74 % to $1.15 billions, compared with the prior year period.

Caleres Inc

Loss Despite Sales Growth

Caleres Inc announced earnings per share of $-0.15 and Sales of $732.23 millions in the forth quarter, Company's slipped into loss per share, versus $0.26 eps, earned in the same quarter a year ago, although Caleres Inc saw it's Sales rise by 5.06 % in the same period.


CELG's Valuation Current
Price to Earnings PE Ratio (TTM) 49.95
Price to Earnings PE Ratio (Expected) 58.26
Price to Sales (TTM) 8.87
Price to Sales (Expected) 10.77
Price to Book 15.09
PEG (TTM) 1.78
CELG's Financial Strength Current
Quick Ratio 2.69
Working Capital Ratio 3.67
Leverage Ratio (MRQ) 2.87
Total Debt to Equity 2.17
Interest Coverage (TTM) 6.75
Debt Coverage (TTM) 0.24
Per Share Current
Earnings (TTM) 2.48 $
Revenues (TTM) 13.99 $
Cash Flow (TTM) 1.61 $
Cash 9.93 $
Book Value 8.22 $
Dividend (TTM) 0 $

• View Valuation Comparisons • View Growth Rates Comparisons

You need to upgrade your Flash Player
CELG's Efficiency Current
Revenue per Employee (TTM) 1,867,798
Net Income per Employee (TTM) 332,535
Receivable Turnover Ratio (TTM) 7.31
Inventory Turnover Ratio (TTM) 0.89
Asset Turnover Ratio (TTM) 0.42
CELG's Profitability Ratio Current
Gross Margin 96.19 %
Operating Margin 31.2 %
Net Margin 14.39 %
Net Cash Flow Margin 21.72 %
Effective Tax Rate (TTM) 15.73 %
Management Effectiveness Current
Return On Assets (TTM) 7.45 %
Return On Investment (TTM) 8.38 %
Return On Equity (TTM) 34.96 %
Dividend Yield -
Payout Ratio (TTM) -
• View Efficiency Comparisons • View Profitability Comparisons • View Management Effectiveness


   
Customers Net Income fell by CELG's customers Net margin fell to %
-21 % 2.79 %
   
• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers
You need to upgrade your Flash Player


You need to upgrade your Flash Player

   
You need to upgrade your Flash Player
Major Competitors Stock performance

5 Days Decrease / Increase
     
LLY        0.09% 
BMY   -0.73%    
MRK        0.22% 
ABT   -0.31%    
PFE   -0.41%    
JNJ   -1.06%    
• View Complete Report
   

Economy

Advance Monthly Sales
Consumer Price Index CPI
Producer Price Index PPI
Retail Inventories
Personal Income
Gross Domestic Product GDP
Money Supply
Industrial Production
Productivity
Employment Situation
US International Trade
Factory Orders
Durable Goods
Construction Spending
Housing Starts
Vehicle Unit Sales
Stocks

Event Calendar
LINC's Profile
Stock Price
LINC's Financials
LINC's Expectations
Business Description
Fundamentals
Charts & Quotes
LINC's News
Suppliers
LINC's Competitors
Customers & Markets
Economic Indicators
LINC's Growth
Company Segments
Industries

At a Glance
Performance
Growth Rates
Profitability
Valuation
Financial Strength
Markets

At a Glance
Stocks
Indices
Sectors & Industries
Financials
Commodities
Currencies
Screening

Stock Performance
Growth Rates
Profitability
Valuation
Dividend
Financial Strength
Efficiency
Expectations
Management Effectivness
News

At a Glance
Stocks
Economy
Industries
Other
Glossary

Financial Terms
Technical Analysis
Fundamental Analysis
Energy Terms
Manufacturing Terms
Transportation Terms
Health Care
Insurance Terms
Economy Terms
Hotel & Leisure Terms
Help

Sitemap
Advertise
About us
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2017 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com